Stada Arzneimittel : Steady Stada
Stada’s bonds have performed decently since the inaugural 2017 high-yield issuance on the back of steadily improving results. Over the past three years, spreads of secured notes have beaten the 'B' index by around 100bp and those of unsecured notes by around 50bp. Stada's issues have also proved less volatile, notably amid the Covid-fuelled market sell-off. The recent acquisitions, all-debt financed and mainly located in emerging countries, have raised eyebrows at rating agencies...Stada Arzneimittel is engaged in the development and marketing of products with off-patent active pharmaceutical ingredients in the health care and, in particular, in the pharmaceutical market. Generics is based on low pricing and/or a cross-product and cross-indication marketing concept while Branded Products focus on the specific product characteristics and, in particular, on the brand name of individual products. Co.'s business activities are divided into the four market regions of Germany, Central Europe, CIS / Eastern Europe and Asia & Pacific & Middle East / North Africa (MENA).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.